GPA is a necrotizing non-caseating granulomatous vasculitis; the vasculitic component distinguishes it pathologically from isolated granulomatous inflammation seen in sarcoidosis
Upper respiratory tract involvement occurs in the majority of GPA patients and is often the presenting feature, yet diagnosis is frequently delayed because symptoms mimic chronic sinusitis
The combination of aggressive destructive bony changes (erosions, perforations, saddle deformity) with mucosal inflammation and soft tissue nodules is highly characteristic of GPA and helps narrow the differential diagnosis
Sclerosing osteitis—manifested by scalloping, sclerosis, and neo-osteogenesis—is a distinctive finding reflecting the chronic inflammatory and fibrotic response of bone to granulomatous vasculitis
Treatment typically involves corticosteroids and cytotoxic agents such as cyclophosphamide; imaging helps establish baseline disease burden and monitor response to therapy
The disease is generally indolent in the upper respiratory tract but can progress to fulminant disease with secondary sepsis requiring antibiotics in addition to immunosuppressive therapy
When reporting GPA with upper respiratory tract involvement, clearly document the pattern of bony destruction (specifying lamina papyracea, septal, and lateral wall erosions), presence of perforation, associated sclerotic bone changes, and extent of mucosal thickening and soft tissue nodules; this constellation of findings should prompt consideration of GPA and comparison with prior imaging or clinical correlation for systemic disease manifestations.